Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva Advancing Two Advair Generics With Late 2017 Target

Executive Summary

Teva will move forward an internal generic Advair candidate and one acquired from Allergan to improve its chances of getting an interchangeable version of the market-leading asthma drug approved by FDA.


Related Content

Advair Competition: Teva’s AirDuo Approved But Not Therapeutically Equivalent
2016 Pharma Dealmaking: Waiting On The High-Value Deals
Mylan Confident On Advair Generic First-Round Approval
Allergan Sees Growth From New Launches, Not Big M&A
Teva CRL Response For Huntington’s Drug Targeted For September
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Teva’s Rosy View For A Happy Union With Allergan Generics
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
US Patent Board To Review Mylan's Copaxone Challenge


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst